INTRODUCTION
============

Cervical cancer is a major worldwide health problem of women especially in developing countries. In Thailand, it is the second most common female cancer after breast cancer and remains the leading cause of death among women. An average age standardized incidence rate was 29.2 per 100,000 women with a death rate of 15.2 per 100,000 women or approximately half of its incidence \[[@B1]\]. This is probably due to a suboptimal screening coverage of the target population, leading to a high proportion of locally advanced and advanced stage diseases and poor overall prognosis \[[@B2]\].

Concurrent chemoradiation therapy (CCRT) has been used as a standard treatment for locally advanced cervical cancer (LACC) for over two decades. Despite a survival improvement with an addition of concurrent chemotherapy to radiation, high rates of local and distant failures (17% and 18%, respectively) were still encountered \[[@B3]\]. A search for other treatments to improve treatment outcomes in this particular group of cervical cancer patients is important.

Many treatment modifications which have been used with CCRT were adding novel targeted agents with chemotherapy, using other chemotherapeutic regimens either alone or in combination with the standard platinum drug, modifying the dose or schedule of chemotherapy, or giving additional chemotherapy (adjuvant or consolidation chemotherapy) after CCRT.

The role of additional chemotherapy after CCRT for LACC has been explored in many studies \[[@B4][@B5][@B6][@B7]\]. Although all prospective phase II studies showed an increased response rate with adjuvant or consolidation chemotherapy with high 80%--90% survival rates \[[@B4][@B5][@B6][@B7]\], the 3 randomized controlled trials of adjuvant chemotherapy (ACT) had inconsistent data \[[@B8][@B9][@B10]\]. Two trials showed increased progression-free survival (PFS) or disease-free survival (DFS) using ACT after CCRT \[[@B9][@B10]\] whereas the other trial could not demonstrate such a benefit \[[@B8]\].

This trial aimed to assess the efficacy of ACT after CCRT compared to standard treatment of CCRT alone. The primary outcome was PFS whereas the secondary outcomes were response rate, overall survival (OS), quality of life and cost-utility of ACT. Quality of life and cost-utility of ACT were presented elsewhere.

MATERIALS AND METHODS
=====================

The parallel superior designed randomized trial was a collaboration among 11 institutions in Thailand. The protocol was approved by the National Central Research Ethics Committee (COA-CREC 002/2013) and was registered under the TCTR (TCTR 20140106001) and the clinical trial.gov trial ([NCT02036164](http://clinicaltrials.gov/ct2/show/NCT02036164)).

1. Sample size {#sec1}
--------------

The sample size was based on the result of a prospective phase II study of Choi et al. \[[@B6]\] who found 15% improvement of PFS in the patients who had ACT after CCRT (70%) compared to CCRT alone (55%). This effect was selected as the smallest effect that would be important to detect, in the sense that any smaller effect would not be of clinical significance. It was also assumed that this effect size could be anticipated in this field of research. The test of hypothesis was 2-tailed with criteria for significance (α) of 0.05. By log-rank test of survival in 2 groups followed for a fixed time and constant hazard ratio (HR), 220 subjects in each group were required to have statistical power at 90% with 158 total number of events required. A total of 500 subjects were planned (250 subjects in each arm).

2. Inclusion criteria {#sec2}
---------------------

The inclusion criteria were: women aged 18 to 70 years; with newly diagnosed cervical cancer of International Federation of Gynecology and Obstetrics (FIGO) stage IIB--IVA (FIGO 2009); an Eastern Cooperative Oncology Group performance score of 0--2; and histopathology of squamous cell carcinoma, adenocarcinoma, or adeno-squamous carcinoma. Adequate bone marrow function defined as white blood count ≥3,000/mm^3^, absolute neutrophil count ≥1,500/mL^3^, platelets ≥100,000/mL^3^; adequate hepatic and renal functions defined as bilirubin ≤1.5× and serum glutamic-oxaloacetic transaminase/serum glutamic-pyruvic transaminase ≤1.5× of the institutional upper normal value; and creatinine clearance ≥40 mg/dL were required. All patients signed informed consent to participate in the study. Patients were excluded if they had para-aortic lymph node enlargement \>1 cm or were suspicious for cancer metastasis from screening computed tomography scan, received other experimental drugs in past 30 days, or had uncontrolled medical illness e.g., chronic renal failure, pre-existing neuropathy, or human immunodeficiency viruses (HIV) infection.

3. Randomization {#sec3}
----------------

The study Consolidated Standards of Reporting Trials diagram is presented in [Supplementary Fig. 1](#S7){ref-type="supplementary-material"}. After the staging procedures were complete, all patients who met all inclusion criteria were randomly assigned to arm A or arm B at week zero using nQuery 7.0 (Stasols, Boston, MA, USA) stratified by disease stage (IIB vs. III to IVA) and histopathology (squamous vs. adenocarcinoma or adenosquamous carcinoma) by mixed block randomization. The block random allocation sequence was obtained by central computerized-generated randomization system. The enrollment and treatment assignment were done by the principal investigators in each hospital.

4. Treatment {#sec4}
------------

Before the project was launched, the investigators from all participating institutions conferred to standardize the radiation instrument and techniques, and the details of chemotherapy treatment. The treatment was required to be initiated within 30 days after randomization and be given in each participating hospital. All patients in both the control (arm A) and study arm (arm B) received weekly cisplatin 40 mg/m^2^ concurrent with pelvic radiation therapy. After CCRT, the patients in arm A had surveillance without any additional treatment. Those in arm B, after a 4-week period, had paclitaxel 175 mg/m^2^ IV plus carboplatin area under the curve 5 IV every 4 weeks for 3 cycles. Detail of radiation and chemotherapy treatment, and dose modification are shown in the [Supplementary Data 1](#S1){ref-type="supplementary-material"}.

5. Clinical outcomes {#sec5}
--------------------

The primary outcome was 3-year PFS. The secondary outcomes were response rate, 3-year OS, adverse events, and cost-utility which included quality of life, direct and indirect cost of treatment. Data of cost-utility were presented elsewhere. The assessment of clinical outcomes is presented in [Supplementary Data 1](#S1){ref-type="supplementary-material"}.

6. Data management and statistical analysis {#sec6}
-------------------------------------------

All data records in each participating hospital were collected and scanned before sending the original copies to the National Medical Research Network group of Thailand (MedResNet, Bangkok, Thailand). All submitted data were verified by the central research coordinators before being transferred to the Data Management Unit of MedResNet.

Data were analyzed using SPSS statistical software, version 22.0 (IBM Corp., Armonk, NY, USA). Data from subgroup analysis were compared by χ^2^ test. Survival data were analyzed by the Kaplan-Meier method and were compared between groups with a log-rank test. The p-values\<0.05 were considered statistically significant. The response rates and survivals were analyzed by modified intent-to-treat including all patients who had at least initiated treatment according to their randomized arms and per protocol including only those who had actual treatment as specified in the protocol. The interim analysis for safety and efficacy of treatment for different outcomes measurement are detailed in [Supplementary Data 1](#S1){ref-type="supplementary-material"}.

RESULTS
=======

1. Patients and baseline characteristics {#sec1___1}
----------------------------------------

From January 2015 to June 2017, 271 eligible patients were enrolled and randomly allocated to either arm A (n=135) or arm B (n=136). Data were suspended in March 2018 for an interim analysis. One patient in each arm had protocol violation (presence of HIV infection) whereas 5 patients in each arm retracted their consent before treatment initiation. Total of 129 patients in arm A and 130 patients in arm B received the allocated treatment. The number of patients who were assigned to each arm, the number and reasons of treatment discontinuation, and number of patients analyzed for each outcome are illustrated in [Supplementary Fig. 1](#S7){ref-type="supplementary-material"}.

Majority of patients were in stage II (62.0% in arm A and 65.4% in arm B). Squamous cell carcinoma was more common (76.0% in arm A and 76.9% in arm B). The median tumor size was 5 cm (range, 2--10 cm) in both arms whereas the median hemoglobin levels were 11.9 g/dL (range, 6.8--14.5 g/dL) in arm A and 11.7 g/dL (range, 4.0--14.7 g/dL) in arm B. Although arm B had 4 patients with stage IVA disease and slightly higher frequency of abnormal imaging of pelvic node, these features and other baseline data between the 2 randomized arms were not significant different. The characteristic features of the patients, stage, histopathology and size of tumor, and hemoglobin level at baseline are shown in [Table 1](#T1){ref-type="table"}.

###### Baseline clinico-pathologic data of patients

![](jgo-30-e82-i001)

  Characteristics                Arm A (n=129)             Arm B (n=130)      
  ------------------------------ ------------------------- ------------------ ------------
  Age (yr)                       50 (26--68)               49 (23--68)        
  Performance status                                                          
                                 0                         115 (89.1)         122 (93.8)
                                 1                         13 (10.1)          8 (6.2)
                                 2                         1 (0.8)            \-
  FIGO stage                                                                  
                                 IIB                       80 (62.0)          85 (65.4)
                                 IIIA                      4 (3.1)            1 (0.8)
                                 IIIB                      45 (34.9)          40 (30.8)
                                 IVA                       \-                 4 (3.1)
  Histopathology                                                              
                                 Squamous cell carcinoma   98 (76.0)          100 (76.9)
                                 Adenocarcinoma            28 (21.5)          26 (20.0)
                                 Adenosquamous carcinoma   3 (2.3)            4 (3.1)
  Imaging of pelvic lymph node                                                
                                 Normal findings           102 (79.1)         95 (73.1)
                                 Abnormal findings         27 (20.9)          35 (26.9)
  Tumor size (cm)                5 (2--10)                 5 (2--10)          
  Hemoglobin (g/dL)              11.9 (6.8--14.5)          11.7 (4.0--14.7)   

Values are presented as median (interquartile range) or number (%).

FIGO, International Federation of Gynecology and Obstetrics.

2. Treatment and compliance {#sec2___1}
---------------------------

Data of treatment during CCRT and ACT are shown in [Table 2](#T2){ref-type="table"}. Thirteen patients (5.0%) did not complete CCRT: 5 in arm A (3.9%) and 8 in arm B (6.2%). The most common reason was a consent withdrawal or loss to follow-up. The median radiation dose and duration of radiotherapy, and median number of cisplatin as well as median hemoglobin level during CCRT were approximate between both arms.

###### Data of radiation treatment
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  Data of treatment   Arm A (n=129)                                  Arm B (n=130)      
  ------------------- ---------------------------------------------- ------------------ -------------------
  CCRT                                                                                  
                      Radiation therapy                              \-                 \-
                      EBPRT                                          \-                 \-
                      Total dose (Gy)                                54 (20--60)        54 (18--62)
  ICRT                                                                                  
                      Total dose point A (Gy)                        28 (0--35)         28 (0--35)
                      Cisplatin cycles                               5 (1--6)           5 (1--6)
                      Overall duration of radiation therapy (days)   58 (10--102)       58 (9--110)
                      Hemoglobin during radiation therapy (g/dL)     11.4 (8.9--13.9)   11.6 (10.0--14.9)
  ACT                                                                                   
                      Not receiving                                  128 (99.2)         30 (23.1)
                      Incomplete radiation treatment                 5                  8
                      1 cycle                                        \-                 7 (5.4)
                      2 cycle                                        \-                 8 (6.2)
                      3 cycle                                        1 (0.78)           85 (65.4)

Values are presented as median (interquartile range) or number (%).

ACT, adjuvant chemotherapy; CCRT, concurrent chemotherapy therapy; EBPRT, external pelvic radiation therapy; ICRT, intracavitary radiation therapy.

Among 130 patients who were allocated to arm B, total of 30 patients (23.1%) did not have ACT: 8 patients did not complete CCRT and 22 declined further treatment or were lost to follow-up after CCRT completion. Total of 85 patients (65.4%) completed 3 cycles of ACT. Other 8 patients (6.2%) had 2 cycles and 7 patients (5.4%) had only 1 cycle. The most common reason for the ACT discontinuation was from prolonged hematologic toxicity or peripheral neuropathy. On the other hand, 1 patient in arm A had ACT and completed 3 cycles of treatment. The reasons for having no or incomplete CCRT or ACT are shown in [Supplementary Table 1](#S2){ref-type="supplementary-material"}.

3. Efficacy {#sec3___1}
-----------

With a median follow-up of 27.4 months (range, 3.2--49.0 months), clinical outcomes of all 259 patients (129 in arm A and 130 in arm B) were included in the interim analysis by a modified intention to treat. After excluding 51 patients who did not have treatment as planned (13 in both arms who did not complete radiation treatment, 1 patient in arm A who had ACT, and 37 patients in arm B who did not have or had incomplete 3 cycles of ACT), data of 208 patients (123 in arm A and 85 in arm B) were analyzed per protocol.

Details of primary tumor response and primary failure including persistence and progression at each month of assessment are described and summarized in [Supplementary Table 2](#S3){ref-type="supplementary-material"}. Overall, the patients in arm B had non-significant higher rate of persistence or progression than in arm A: 13.1% vs. 5.9% (p=0.154). On the contrary, the recurrence was higher in arm A than arm B: 15.5% vs. 10.8% (p=0.123). Summary data of response rates, failure of treatment and sites of failure are shown in [Table 3](#T3){ref-type="table"} and described in detail in [Supplementary Data 1](#S1){ref-type="supplementary-material"}.

###### Treatment outcomes of cervical cancer patients by an intention to treat analysis (n=259)
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  Outcomes of treatment   Arm A (n=129)                Arm B (n=130)   p-value                  
  ----------------------- ---------------------------- --------------- ------------ ----------- -------
  Response                                                                                      
                          Complete response            112 (86.8)      100 (76.9)   0.114       
                          Primary failure              17 (13.2)       30 (23.1)                
                                                       Persistence     10 (7.8)     21 (16.2)   0.037
                                                       Progression     7 (5.4)      9 (6.9)     0.617
  Recurrence              20 (15.5)                    14 (10.8)       0.123                    
                          Loco-regional                4 (3.1)         4 (3.1)      0.871       
                          Systemic                     13 (10.1)       7 (5.4)      0.029       
                          Loco-regional and systemic   3 (2.3)         3 (2.3)      0.910       
  Status                                                                                        
                          Alive                        108 (83.7)      101 (77.7)   0.254       
                          Dead of disease              21 (16.3)       29 (22.3)    \-          

Values are presented as number (%).

Various types of management were given to the patients after failure of treatment. Chemotherapy (with or without other modalities) and surgery were used more frequently among the patients in arm A than those in arm B whereas palliative radiation, supportive care, or loss to follow-up were more commonly found among the patients in arm B ([Supplementary Table 3](#S4){ref-type="supplementary-material"}).

4. Survival {#sec4___1}
-----------

The 3-year PFS was 3.2% lower in arm B than in arm A: 63.4% (95% CI=54.6%--72.2%) vs. 66.6% (95% CI=57.4%--75.8%) respectively ([Supplementary Fig. 2](#S8){ref-type="supplementary-material"}). The HR was 1.26 (95% CI=0.82--1.96; p=0.293). Overall, 20.8% of the patients in arm B and 14.0% in arm A were dead of diseases (p=0.219). Details of number and cause of deaths are described in [Supplementary Data 1](#S1){ref-type="supplementary-material"}. The 3-year OS was 10.6% lower in arm B than in arm A: 69.5% (95% CI=59.3%--79.7%) vs. 80.1% (95% CI=71.9%--88.3%) respectively ([Supplementary Fig. 3](#S9){ref-type="supplementary-material"}). The HR was 1.42 (95% CI=0.81--2.49; p=0.221).

Sensitivity analysis by stage (age \<40 vs. older, stage II vs. III--IV, histopathology of squamous cell carcinoma vs. adeno-or adenosquamous carcinoma, and duration of radiation therapy did not show any differences in outcomes between these subgroups ([Supplementary Table 4](#S5){ref-type="supplementary-material"}).

Additionally, we conducted a non-parametric bootstrap analysis to explore the uncertainty of the findings. The analysis further supported that there was uncertainty regarding the effect of ACT on PFS and OS of the patients. Taken into consideration the futility of additional chemotherapy, further recruitment of the patients was determined as inappropriate especially in our country which has limited economical resources.

5. Per protocol analysis {#sec5___1}
------------------------

We analyzed data of 208 patients (123 in arm A and 85 arm B) per protocol. Response rates at 4 months, recurrence and deaths were not significantly different between the 2 groups. The response rates evaluated at each time point after treatment by intention to treat and per protocol are shown in details in [Supplementary Table 2](#S3){ref-type="supplementary-material"} whereas the summary of outcomes per the protocol analyses are shown in [Supplementary Table 5](#S6){ref-type="supplementary-material"}.

6. Adverse events {#sec6___1}
-----------------

The overall numbers and percentages of patients who experienced grades 1--2 and grades 3--4 adverse events are shown in [Table 4](#T4){ref-type="table"}. The most common toxicity found in both arms was hematologic toxicity (particularly anemia and neutropenia). Grades 3--4 anemia were similarly found in arm A (3.1%) and arm B (5.4%). However, neutropenia of grades 3--4 were found slightly higher than 2 folds in arm B (13.1%) than arm A (6.2%). On the other hand, 65 patients in arm A had 105 adverse events during CCRT phase whereas 83 patients in arm B developed 223 adverse events (109 events during CCRT with an addition of 124 events during ACT).

###### Acute toxicities during in patients who had concurrent chemoradiation (arm A) or concurrent chemoradiation followed by adjuvant chemotherapy (arm B)
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  Adverse event   Arm A (n=129)            Arm B (n=130)                         
  --------------- ------------------------ --------------- --------- ----------- -----------
  Hematology                                                                     
                  Anemia                   26 (20.2)       4 (3.1)   35 (26.9)   7 (5.4)
                  Leukopenia               1 (0.8)         \-        5 (3.8)     \-
                  Neutropenia              19 (14.7)       8 (6.2)   26 (20.0)   17 (13.1)
                  Platelets                3 (2.3)         1 (0.8)   12 (9.2)    5 (3.8)
                  Gastrointestinal tract   13 (10.1)       3 (2.3)   11 (8.5)    6 (4.6)
                  Genitourinary tract      11 (8.5)        2 (1.6)   2 (1.5)     4 (3.1)
                  Muskuloskeletal          1 (0.8)         \-        3 (2.3)     \-
                  Neurologic               \-              \-        10 (7.7)    4 (3.1)
                  Dermatology              1 (0.8)         \-        11 (8.5)    1 (0.8)
                  Laboratory findings      7 (5.4)         2 (1.6)   4 (3.1)     2 (1.5)
                  General                  2 (1.6)         \-        8 (6.2)     \-

Values are presented as number (%). Some patients may have more than 1 adverse effects.

DISCUSSION
==========

Because CCRT which is the current standard treatment for LACC could yield only 60%--65% survival rate \[[@B3]\], other alternative treatments were considered. One option was to give additional chemotherapy after the completion of CCRT in order to eradicate any residual tumor either inside the pelvis or beyond.

This trial gave additional chemotherapy with paclitaxel and carboplatin for 3 more cycles after CCRT. However, the results did not show any improvement of PFS or OS by ACT. On the contrary, the patients who had additional ACT had lower 3-year PFS (3.2%) and 3-year OS (10.6%) compared to those who had only standard CCRT. Although the differences were not statistically significant, these were rather unexpected. The bootstrap analysis confirmed uncertainty in outcomes, suggesting a non-significant difference of the 2 types of intervention. Further recruitment and a certain period of follow-up would be unlikely to provide a definite answer and would be inappropriate in our country setting with limited resources.

The inconclusive results from this trial added more uncertainty to the unanswered question regarding the role of ACT after CCRT. Findings from the 3 previous randomised controlled trials (RCTs) comparing CCRT to CCRT and ACT were inconsistent \[[@B8][@B9][@B10]\]. Two trials showed significant survival benefit of ACT over CCRT alone \[[@B9][@B10]\]. One of which was an international collaboration reported 9% (74% vs. 65%) 3-year PFS and 11% (80% vs. 69%) 3-year OS improvement by the use of ACT \[[@B9]\] whereas another trial from China reported 11% 5-year DFS improvement (71% vs. 60%) with 7% lesser deaths (26% vs. 33%) \[[@B10]\]. However, there was a discrepancy of standard treatment between the 2 randomized arms of both trials. One trial gave combined chemotherapeutic drugs during CCRT (cisplatin plus gemcitabine) before ACT of the same regimen in the study arm compared to single agent (cisplatin) during CCRT before observation in the control arm \[[@B9]\] whereas another trial gave neoadjuvant chemotherapy (cisplatin plus paclitaxel) prior to CCRT (cisplatin) then ACT (cisplatin plus paclitaxel) compared to CCRT alone (cisplatin) \[[@B10]\]. These discrepancies should be taken into account when considering the benefit of ACT. Data from these previous trials and our trial are summarized in [Table 5](#T5){ref-type="table"}.

###### Comparison of data of our trial and previous trials of ACT after concurrent chemoradiation in locally advanced cervical cancer
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  Features/trial                      Lorvidhaya et al., 2003 \[[@B8]\]                                  Dueñas-González et al., 2011 \[[@B9]\]                              Tang et al., 2012 \[[@B10]\]                                              This trial                                         
  ----------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------- ------------------------------------
  Number                              463^†^                                                             515                                                                 880                                                                       259                                                
  Stage^\*^                           IIB to IVA                                                         IIB to IVA                                                          IIB to IVA                                                                IIB to IVA                                         
  Other pre-requisites                Tumor in IIB \>3 cm or involved \>1/2 PRM (imaging not required)   Patients with PAN \>1 cm must be FNA negative                       Patients with +ve PAN from CT scan had EFRT                               Excluded patients with +ve PAN from imaging        
  Histopathology                      SCC, ACA                                                           SCC, ACA, AS                                                        ACA only                                                                  SCC, ACA, AS                                       
  Neoadjuvant CMT                     None                                                               None                                                                Paclitaxel/cisplatin 1 cycle                                              None                                               
  Concurrent CMT                      Mitomycin/oral 5-FU in both arms                                   Cisplatin in CCRT arm                                               Cisplatin in both arms                                                    Cisplatin in both arms                             
  Cisplatin/gemcitabine in ACT arm                                                                                                                                                                                                                                                                        
  Adjuvant CMT                        Oral 5-FU 3 cycles                                                 Cisplatin/gemcitabine 2 cycles                                      Paclitaxel/cisplatin 2 cycles                                             Paclitaxel/carboplatin 3 cycles                    
  Incomplete Rx                       5% in CCRT arm                                                     0.4% in CCRT arm (during CCRT)                                      None                                                                      4% in CCRT arm (during CCRT)                       
  8% in ACT arm (phase, NOS)          5% (during CCRT), 24% (during ACT) in ACT arm                      6% (during CCRT), 36% (during ACT) in ACT arm                                                                                                                                                    
  Outcomes                                                                                                                                                                                                                                                                                                
                                      Median follow-up                                                   89 mo                                                               46.9 mo                                                                   60 mo (range 9--120 mo)                            27.4 mo (range, 3.2--49.0 mo)
                                      Tumor response                                                     NA                                                                  CCRT vs. ACT (timing after CCRT)                                          CCRT vs. ACT (timing after CCRT)                   CCRT vs. ACT (timing after CCRT)
  93% (1 mo) vs. 96% (3 mo)           47% vs. 71% (after CCRT ended)                                     59% vs. 42% (after CCRT ended)                                                                                                                                                                   
  75% vs. 86% (1 mo)                  75% vs. 58% (1 mo)                                                                                                                                                                                                                                                  
  75% vs. 96% (3 mo)                  88% vs. 68% (3 mo)                                                                                                                                                                                                                                                  
  94% vs. 87% (4 mo)                                                                                                                                                                                                                                                                                      
                                      Survival                                                           No benefit of ACT after CCRT                                        HRs=0.68 (p=0.02; 95% CI=0.49--0.95) for both PFS & OS in favor ACT arm   5-yr DFS: 63% CCRT arm vs. 75% ACT arm (p\<0.05)   3-yr PFS: 67% CCRT vs. 63% ACT arm
  3-yr OS: 80% CCRT vs. 63% ACT arm                                                                                                                                                                                                                                                                       
  Sites of failure                    Slightly higher failure at all sites in ACT arm (NS)               Lower failure at all sites in ACT arm (sig. only distant failure)   Lower failure at all sites in ACT arm (sig. in all differences)           Lower only distant failure in ACT arm (sig.)       

ACA, adenocarcinoma; ACT, adjuvant chemotherapy; AS, adenosquamous carcinoma; CCRT, concurrent chemoradiation therapy; CMT, chemotherapy; CT, computed tomography; EFRT, extended field radiation therapy; FNA, fine needle aspiration; HR, hazard ratio; PFS, progression-free survival; SCC, squamous cell carcinoma; NOS, not otherwise specified; NS, not significant; +ve, positive.

^\*^Stage in all trials (except Lorvidhaya\'s trial) followed the International Federation of Gynecology and Obstetrics 2009; ^†^Number in the Lorvidhaya trial included only the patients in arm 3 (CCRT) and arm 4 (CCRT plus ACT)

Although the results from our study were similar to the findings of 1 trial from Thailand which showed insignificantly lower 5-year DFS (60% vs. 65%) and 5-year OS among the patients who had ACT than those who had only CCRT \[[@B8]\], the underlying reasons may be different. The possible reason for negative findings in their trial was the questionable compliance of oral 5-FU which was used as an ACT \[[@B8]\].

There were a few possible reasons that our study could not demonstrate the benefit of ACT in LACC patients. First, the chemotherapeutic regimen of paclitaxel and carboplatin may not be effective. Previous trials used different chemotherapy regimens in the concurrent phase with radiation and/or the adjuvant phase: mitomycin C with oral 5-FU \[[@B8]\], cisplatin with paclitaxel \[[@B10]\] or with gemcitabine \[[@B9]\]. Instead of paclitaxel and cisplatin which showed similar efficacy with other doublets chemotherapy in a randomized controlled trial of advanced or recurrent cervical cancer \[[@B11]\], our study selected paclitaxel and carboplatin as ACT because of its convenience and feasibility in administration. Furthermore, we assumed from available data of the non-inferior activity of this chemotherapeutic regimen in cervical cancer \[[@B12][@B13]\]. Upon a careful re-scrutinization, most data which showed comparable efficacy of the 2 regimens were derived from retrospective \[[@B12]\] or a systemic review including only retrospective or phase II studies \[[@B13]\], and only 1 randomized trial \[[@B14]\]. Furthermore, data from 1 randomized trial demonstrated that paclitaxel/carboplatin was inferior to paclitaxel/cisplatin in advanced non-small cell lung cancer \[[@B15]\]. More evidence-based data of this chemotherapy regimen\' efficacy in cervical cancer may be needed. Second, the chemotherapy cycles may be inadequate. An example is the ACT in epithelial ovarian cancer which is generally given for 6 or more cycles to maximize the efficacy especially in advanced stages. Our group postulated that 3 cycles of additional chemotherapy should be adequate to demonstrate the efficacy of the adjuvant treatment. Furthermore, the extended duration of approximately 3 months would not be too long to burden the patients and their family, and the direct and indirect medical cost incurred would not be too high. Third, a possible selective benefit of ACT on a more advanced stage or certain histopathology (adenocarcinoma in particular) was diluted by including stage II patients or squamous cell carcinoma which comprised the major cervical cancer population whose diseases could be managed by CCRT alone. This was partly supported by findings from the study of Dueñas-González et al. \[[@B9]\] which found a higher benefit of ACT in stage III--IV or adenocarcinoma. Although our subgroup analyses did not show any particular groups of patients who may have benefit from ACT, limited sample size precluded any conclusion. Another reason was that the ACT really had no benefit in LACC. This last reason was supported by data from the 2 alternative statistical means of per protocol and bootstrap analyses. Although a considerable number of patients were dropped out before treatment completion especially among those who were assigned to ACT, the results from per protocol and bootstrap analyses were consistent with those from the modified intention to treat analyses. Additionally, the insignificant findings could be due to the fact that the final sample size was lower than expected, which translated to uncertainty in findings on the impact of ACT on LACC patients.

Limitations of our study included poor compliance of the patients in the trial. The discontinuation rates during CCRT were not significantly different between 2 treatment arms. We found 17.6% of all patients who were randomized to have ACT did not have any ACT (or 18.7% among those who had complete CCRT). The main reason of the discontinuation in our study was rather from the patients\' decision or lost to follow-up than from the toxicity. We postulated that the alleviation of symptoms after treatment combined with the deviation of daily lives activities coming to the hospital especially in a setting with long treatment duration of treatment might have influenced their decisions despite their consent to enter into the trial in the beginning. Furthermore, most Thai cervical cancer patients had low socioeconomic status and education, they were tempted to take herbal or alternative treatments despite non-proven efficacy. One previous study in an urban academic cancer center reported 20% non-compliance among patients who had radiation treatment \[[@B16]\]. Having cervical or uterine cancer, low socioeconomic status, and a long treatment course were among several predicting factors of the non-compliance. Among the 3 previous trials, 1 trial found that all 880 cervical cancer patients in their study completed treatment \[[@B10]\] whereas the other 2 trials reported the discontinuation rates \[[@B8][@B9]\]. The trial of Lorvidhaya et al. \[[@B8]\] reported 7% of the patients (5% in the CCRT and 8% in the ACT groups) had incomplete treatment. However, the authors did not detail the timing and reason of the discontinuation. Another trial of Dueñas-González et al. \[[@B9]\] reported a significantly higher number of patients in the study arm discontinued treatment during the pre-adjuvant phase, most frequently from side effects (5% in the study arm vs. 0.4% in the control arm). This was rather predictable because their patients in the study arm had combination of chemotherapy (cisplatin with gemcitabine) in concurrent with pelvic radiation compared to those in the control arm who had only a single agent (cisplatin) \[[@B9]\]. Toxicity was also a reason for the ACT omission or discontinuation in their study which was reported in 14% and 10% respectively \[[@B9]\].

In an assessment of response rates, we were aware of the delayed efficacy of radiation therapy. Hence, our study explored the tumor shrinkage at 4 different time points after CCRT. This was found in our study as the tumors shrank over time in both arms. Although the rates of tumor shrinkage were observed to be significantly higher in arm A than in arm B during the first 3 months (despite a balance of characteristic features between both arms), the magnitudes of incremental response between the assessments were higher in arm B especially at the fourth evaluation (a time point in determining tumor response) leading to a non-significant difference of the response rates at 4 months after CCRT or approximately 1 month after the last cycle of ACT. This may be considered as indirect evidence for the benefit of ACT especially when all 3 cycles could be given. Among the 3 RCTs comparing standard CCRT and CCRT followed by ACT, only 2 trials which reported the response outcomes had inconsistent findings \[[@B9][@B10]\]. The international trial by Dueñas-Gonzalez et al. \[[@B9]\] who did not find significant differences in response rates between the patients who had only CCRT or CCRT and ACT, 93% vs. 96%. These comparable response rates were despite the disparity of concurrent chemotherapy during radiation treatment. Another study from China found significantly higher response rate in the patients who had additional chemotherapy \[[@B10]\]. The response rates evaluated at 1 month after CCRT were 75% in the CCRT group and 86% in the ACT group. The rate increased to 96% in the latter group after ACT. However, the benefit of ACT in this trial was questionable because the study arm also had 1 cycle of paclitaxel and cisplatin as the neoadjuvant chemotherapy before CCRT and 2 more cycles of ACT \[[@B10]\].

Theoretically, ACT after CCRT in LACC should increase local pelvic control and decrease systemic failure. A significant lower systemic failure in the patients who had ACT in our study ([Table 3](#T3){ref-type="table"}) was consistent with findings in the 2 trial of Dueñas-González et al. \[[@B9]\] and Tang et al. \[[@B10]\] who also found significantly lower distant failure with an addition of ACT compared to only CCRT: 8%--14% vs. 16%--24%. The only trial of Lorvidhaya et al. \[[@B8]\] found no benefit of ACT on the overall failure rate (29% by CCRT vs. 31% by CCRT and ACT) or the sites of failure (14% and 18% of loco-regional and 18% vs. 20% distant failures). The oral chemotherapeutic drug used in this last trial may preclude the benefit ACT if any.

Concerning the toxicity of the additional treatment, our study found higher frequency of adverse events in arm B than in arm B ([Table 4](#T4){ref-type="table"}). However, some adverse events found in the ACT arm may be the prolonged effects from the CCRT and the figures may not the genuine effect for ACT itself. Anyway, grade 3--4 toxicities were infrequent in both arms with hematologic toxicity as the most common adverse events reported. The 3 previous trials of ACT which reported acute with or without long-term adverse events found slightly higher (not significant) among the patients who had ACT \[[@B8][@B9][@B10]\]. Our long-term adverse events as well as quality of life of the patients were collected and would be reported along with the long-term survival outcomes in another report.

In conclusion, no significant benefit of paclitaxel with carboplatin given for 3 cycles after a standard concurrent chemoradiation treatment for LACC was demonstrated. Future studies might reconsider recruiting the patients with certain high-risk features, adjustment of chemotherapy regimen or cycles, or other alternative treatment options to improve survival outcomes of these patients. Adaptive randomization in favor of standard treatment with CCRT may also be considered.
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